Molecular docking and dynamics simulation of milk kefir metabolites as potential estrogen receptor alpha (ER-α) modulators for breast cancer therapy
Journal of Herbmed Pharmacology · 01.01.2026 · 15 (1) · 135-147
DOI: 10.34172/jhp.2026.52879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Herbmed Pharmacology, online erschienen am 01.01.2026. Verfasst von Ivan Andriansyah und 5 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
Milk kefir, a fermenting milk made with kefir grains, has shown potential in promoting apoptosis, regulating the cell cycle, and reducing tumor growth in breast cancer cells. This study aimed to investigate the stability and potential of milk kefir metabolites as inhibitors of breast cancer growth by interacting with the estrogen receptor alpha (ER-α), a key protein involved in breast cancer cell proliferation. We used computational methods, specifically molecular docking simulations with AutoDock and molecular dynamics (MD) simulations with Gromacs, to analyze how these metabolites bind to ER-α.
Methods
A combination of molecular docking and MD simulations was used to explore how metabolites derived from milk kefir interact with ER-α, a crucial target in breast cancer therapy. The methodology included multiple stages: preparation of target proteins, preparation and screening of the metabolites, geometry optimization, molecular docking, and MD simulations.
Results
The molecular docking simulations of 43 metabolites revealed three promising candidates: 2-Methyl (S35), benzeneethanol (S42), and 2,6-dimethyl-4-heptanone (S54), with binding affinities (ΔG) of -5.08, -5.06, and -4.90 kcal/mol, respectively. MD simulations further showed that the selected metabolites stabilized the ER-α-metabolite complex, with the 2,6-dimethyl-4-heptanone (S54) metabolite demonstrating the most negative total MM-GBSA energy value (ΔG = -22.98 kcal/mol), indicating a strong and stable binding interaction.
Conclusion
2,6-Dimethyl-4-heptanone, a metabolite from milk kefir, showed promising potential as a candidate for further development as a breast cancer treatment, offering a novel alternative to conventional therapies.
Zitieren
APA
Andriansyah, I., Susilo, S., Muhsinin, S., Febrina, E., Aligita, W., & Asnawi, A. (2026). Molecular docking and dynamics simulation of milk kefir metabolites as potential estrogen receptor alpha (ER-α) modulators for breast cancer therapy. Journal of Herbmed Pharmacology, 15(1), 135-147. https://doi.org/10.34172/jhp.2026.52879
Vancouver
Andriansyah I, Susilo S, Muhsinin S, Febrina E, Aligita W, Asnawi A. Molecular docking and dynamics simulation of milk kefir metabolites as potential estrogen receptor alpha (ER-α) modulators for breast cancer therapy. Journal of Herbmed Pharmacology. 2026;15(1):135-147. doi:10.34172/jhp.2026.52879
BibTeX
@article{Andriansyah2026,
author = {Andriansyah, Ivan and Susilo, Salwaa and Muhsinin, Soni and Febrina, Ellin and Aligita, Widhya and Asnawi, Aiyi},
title = {Molecular docking and dynamics simulation of milk kefir metabolites as potential estrogen receptor alpha (ER-α) modulators for breast cancer therapy},
journal = {Journal of Herbmed Pharmacology},
year = {2026},
volume = {15},
number = {1},
pages = {135--147},
doi = {10.34172/jhp.2026.52879}
}
EUVIMED